DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million people are estimated to be living with FSGS in the territories [1] Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481 [2] million, plus royalties US$10 million (~AU$14.1 million 2 ) upfront payment Up to US$330 million (~AU$467 million 2 ) in potential